OBJECTIVES: Increased prevalence of deep white matter hyperintensities (DWMHs) has been consistently observed in patients with geriatric depression and bipolar disorder. DMWHs are associated with chronicity, disability, and poor quality of life. They are thought to be ischemic in their etiology and may be related to the underlying pathophysiology of mood disorders in the elderly. Notably, these lesions strikingly resemble radiological findings related to the cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephelopathy (CADASIL) syndrome. CADASIL arises from mutations in Notch3, resulting in impaired signaling via cellular Fas-associated death domain-like interleukin-1-beta-converting enzyme-inhibitory protein (c-FLIP) through an extracellular signal-regulated kinase (ERK)-dependent pathway. These signaling abnormalities have been postulated to underlie the progressive degeneration of vascular smooth muscle cells (VSMC). This study investigates the possibility that the anticonvulsant valproate (VPA), which robustly activates the ERK mitogen-activated protein kinase (MAPK) cascade, may exert cytoprotective effects on VSMC through the Notch3/c-FLIP pathway. METHODS: Human VSMC were treated with therapeutic concentrations of VPA subchronically. c-FLIP was knocked down via small interfering ribonucleic acid transfection. Cell survival, apoptosis, and protein levels were measured. RESULTS: VPA increased c-FLIP levels dose- and time-dependently and promoted VSMC survival in response to Fas ligand-induced apoptosis in VSMC. The anti-apoptotic effect of VPA was abolished by c-FLIP knockdown. VPA also produced similar in vivo effects in rat brain. CONCLUSIONS: These results raise the intriguing possibility that VPA may be a novel therapeutic agent for the treatment of CADASIL and related disorders. They also suggest that VPA might decrease the liability of patients with late-life mood disorders to develop DWMHs.
OBJECTIVES: Increased prevalence of deep white matter hyperintensities (DWMHs) has been consistently observed in patients with geriatric depression and bipolar disorder. DMWHs are associated with chronicity, disability, and poor quality of life. They are thought to be ischemic in their etiology and may be related to the underlying pathophysiology of mood disorders in the elderly. Notably, these lesions strikingly resemble radiological findings related to the cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephelopathy (CADASIL) syndrome. CADASIL arises from mutations in Notch3, resulting in impaired signaling via cellular Fas-associated death domain-like interleukin-1-beta-converting enzyme-inhibitory protein (c-FLIP) through an extracellular signal-regulated kinase (ERK)-dependent pathway. These signaling abnormalities have been postulated to underlie the progressive degeneration of vascular smooth muscle cells (VSMC). This study investigates the possibility that the anticonvulsant valproate (VPA), which robustly activates the ERK mitogen-activated protein kinase (MAPK) cascade, may exert cytoprotective effects on VSMC through the Notch3/c-FLIP pathway. METHODS:HumanVSMC were treated with therapeutic concentrations of VPA subchronically. c-FLIP was knocked down via small interfering ribonucleic acid transfection. Cell survival, apoptosis, and protein levels were measured. RESULTS:VPA increased c-FLIP levels dose- and time-dependently and promoted VSMC survival in response to Fas ligand-induced apoptosis in VSMC. The anti-apoptotic effect of VPA was abolished by c-FLIP knockdown. VPA also produced similar in vivo effects in rat brain. CONCLUSIONS: These results raise the intriguing possibility that VPA may be a novel therapeutic agent for the treatment of CADASIL and related disorders. They also suggest that VPA might decrease the liability of patients with late-life mood disorders to develop DWMHs.
Authors: Jose M de Asis; Blaine S Greenwald; George S Alexopoulos; Dimitris N Kiosses; Manzar Ashtari; Moonseong Heo; Robert C Young Journal: Am J Geriatr Psychiatry Date: 2006-07 Impact factor: 4.105
Authors: Hak-Joon Sung; Suzanne G Eskin; Yumiko Sakurai; Andrew Yee; Noriyuki Kataoka; Larry V McIntire Journal: Ann Biomed Eng Date: 2005-11 Impact factor: 3.934
Authors: M Michaelis; T Suhan; U R Michaelis; K Beek; F Rothweiler; L Tausch; O Werz; D Eikel; M Zörnig; H Nau; I Fleming; H W Doerr; J Cinatl Journal: Cell Death Differ Date: 2006-03 Impact factor: 15.828
Authors: David Morrow; Agnieszka Scheller; Yvonne A Birney; Catherine Sweeney; Shaunta Guha; Philip M Cummins; Ronan Murphy; Dermot Walls; Eileen M Redmond; Paul A Cahill Journal: Am J Physiol Cell Physiol Date: 2005-06-29 Impact factor: 4.249
Authors: Patrick A Glover; Eric D Goldstein; Mohammed K Badi; Tara J Brigham; Elizabeth R Lesser; Thomas G Brott; James F Meschia Journal: Neurol Clin Pract Date: 2020-12